Rearch homepage new banner Nov 2013

AstraZeneca is a global biopharmaceutical company with research and development at its core

Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination


Vanderbilt and AstraZeneca: Partnering to help patients with major brain disorders

An IMED Collaboration Update

Our research collaboration with the Vanderbilt Center for Neuroscience Drug Discovery aims to identify candidate drugs for treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia. Together, we hope to enable breakthrough discoveries and bring new medicines to patients suffering from these diseases.

Download collaboration update (PDF 292kb)  
 

View more collaboration updates


Our leaders iconOur leaders

All Directors are collectively responsible for the success of AstraZeneca. Discover general information,  images and biographies of our Board of Directors.

Read more


Pipeline iconOur pipeline

AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.

Read more


Path to meds iconPath to new medicines

The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.

Read more


Neuro iconAZ Neuroscience

Visit our dedicated neuroscience site for more information on our research and partnering in the area.

 

Visit site


Open innovation iconOpen innovation

Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines

Visit site


LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

David_Andrews_THM 24 November 2014

AstraZeneca Scientist is Appointed as Royal Society of Chemistry Industrial Associate to Advance Open Innovation

Collab_in_practice_THM 20 November 2014

Collaboration in practice – partnering to accelerate drug discovery

Outcomes_trials_THM 14 November 2014

Outcomes trials: the foundation of evidence-based cardiovascular medicine